Articles tagged with Cancer Immunotherapy
Recent trials have shown that testing for tumour DNA in the blood can identify advanced bladder cancer patients who are less likely to relapse after surgery, allowing doctors to target treatments more effectively.
Researchers assessed the feasibility of dual PD-L1/CTLA-4 checkpoint inhibition in Stage II or III hormone receptor-positive, HER2-negative breast cancer. Eight patients received upfront durvalumab and tremelimumab prior to neoadjuvant chemotherapy, showing mixed responses and limited benefit.
Researchers developed a method using lipid nanoparticles to activate T cells and deliver genetic instructions in one step, simplifying the CAR T cell manufacturing process. This new approach reduces production time from 48 hours to 24 hours and increases accessibility to patients worldwide.
Purdue University researchers create biocompatible nanoparticles modified with ATP that slowly release anti-cancer drugs and recruit immune cells to fight tumors. In mouse studies, these nanoparticles improved the effectiveness of paclitaxel against various types of cancers, including those in distant locations.
A new therapy combines gene-modified dendritic cells with immunotherapy to promote a stronger immune response against lung cancer. The treatment slows down tumor growth and activates T cells to attack cancer cells systemically.
Researchers present findings on immunotherapy approaches, a potential biomarker for neuroendocrine carcinomas, and improved treatments for pancreatic cancer and melanoma. A UCLA team identified UCHL1 as a molecular indicator and therapeutic target for aggressive neuroendocrine cancers.
Researchers have discovered a new immunotherapy approach to overcome resistant leukemia by targeting the mutated TP53 gene. Combining pharmacological therapies with genetically engineered CAR T-cells increases effectiveness against cancer cells, offering promising strategies for patients with resistant disease.
The ALEXANDRA/IMpassion030 phase 3 trial found that adding atezolizumab to chemotherapy after surgery did not improve survival for early-stage triple-negative breast cancer patients. Researchers also found no benefit in different sub-groups, such as those with lymph node spread and PD-L1 positive cancer.
A new genetic test has identified patients with triple negative early-stage breast cancer who are unlikely to respond to immunotherapy drugs. The test, called ImPrintTN, can predict a patient's likelihood of responding to these treatments and help avoid severe side effects.
A new study from Johns Hopkins Medicine found that circulating tumor DNA levels can accurately assess how gastroesophageal cancers respond to treatment and predict future prognosis. The study tracked minimal residual disease by analyzing ctDNA, showing a correlation between ctDNA clearance and cancer-free survival.
New data show that adding pembrolizumab to chemotherapy before and after surgery for breast cancer leads to better outcomes, with significant increases in pathological complete response rates across all age groups. The study also found similar rates of breast-conserving surgery and mastectomy, as well as lower residual cancer burdens.
A study by UNC researchers found that a metabolic enzyme called Acetyl-CoA Carboxylase (ACC) causes T cells to store fat rather than burning it for energy in solid tumors. Inhibiting ACC expression allowed T cells to persist better in tumors, leading to potential breakthroughs in immunotherapies like CAR T-cell therapies.
Researchers have identified specific bacterial strains linked to a positive response to combination immunotherapy in rare gynaecological cancers, biliary tract cancers, and melanoma. A microbiome signature can predict individual responses to treatment, paving the way for personalized medicine and next-generation probiotics.
Seven high-impact studies will be showcased, exploring novel therapies and improving treatment outcomes for patients with head and neck squamous cell carcinoma. These findings highlight advancements in immunotherapy, risk-directed adjuvant therapy, and FDG-PET-based selective de-escalation of radiotherapy.
Researchers developed an oxidative stress-based prognostic model for bladder cancer, identifying distinct molecular subtypes and predicting patient outcomes. The model shows promise in tailoring personalized treatment approaches, particularly for patients with low-risk profiles.
Researchers at City of Hope have developed a new approach to target and destroy hard-to-kill leukemia stem cells. The therapy method uses Type II interferon to disrupt the cancer cells' ability to divide, and a T cell engager antibody to create a bridge between the immune system and the leukemia stem cells.
A combination of CS1002 and CS1003 showed promising anti-tumor activity and a manageable safety profile across various dosing ranges in patients with advanced solid tumors. The treatment was found to be effective in certain types of cancers, including melanoma and skin cancer.
A subset of blood cells, specifically neutrophils expressing the Ly6Ehi protein, can predict immunotherapy treatment response in cancer patients. This discovery has the potential to improve patient outcomes by enabling more targeted and effective treatments.
Researchers highlight difficulties in targeting metastatic tumors and propose two- and three-drug combinations to achieve effective tumor control. They also emphasize the need for simultaneous blocking of primary driving oncogene, evolving resistance mechanism, and secondary survival pathway.
A new genetic signature of 140 genes may predict enhanced disease-free survival in patients with non-small cell lung cancer treated with immunotherapy and low-dose radiation. The signature is associated with aggressive tumor growth but also increased immunity and tissue repair after treatment.
A study by UC Davis Health found that a single dose of BCG reduced liver tumor burden and extended the survival of mice with liver cancer. The vaccine boosted the body's immunity, leading to tumor shrinkage and improved liver function.
A recent study used AI trained on cell-to-cell communication networks to predict drug responsiveness in immunotherapy for cancer. The model demonstrated high accuracy in analyzing samples from 700 patients with four types of cancer, identifying key communication pathways related to responsiveness and resistance.
Researchers have developed a new immunotherapy based on STAb cells that outperforms existing CAR-T treatment in laboratory trials. The new therapy recruits natural T cells to fight cancer cells and overcomes limitations of current treatments.
Researchers identify a promising prognostic biomarker for lung cancer using circulating tumor DNA-based minimal residual disease detection. The study found that this method can effectively guide treatment decisions and predict recurrence risk, potentially modifying the lung cancer treatment paradigm.
A research team has identified an immune biomarker that explains why some patients with hepatocellular carcinoma (HCC) fail to respond to immunotherapy. The biomarker could lead to the development of new immunotherapies by restoring an effective immune response against HCC.
A Phase II trial found that neoadjuvant immunotherapy significantly reduced residual tumor and improved overall survival for patients with undifferentiated pleomorphic sarcoma, with 90% having less than 15% viable tumor cells remaining. The treatment approach is a promising option for patients with limited systemic therapy options.
A new study has identified a genetic marker that can predict which patients are likely to respond to immunotherapy in various types of cancer. Tumors with high intragenic rearrangement (IGR) burden, which indicates cryptic structural rearrangements of the genetic code, may respond better to immunotherapy.
Researchers develop a new strategy to make CAR T cell therapy more effective and safer by targeting multiple surface proteins on malignant tumour cells. The approach shows promise in fighting cancer cells while sparing healthy B lymphocytes.
Researchers discovered that VISTA induces immune suppressor cells called myeloid-derived suppressor cells (MDSCs) through a feedback loop involving STAT3 and polyamines. This pathway has high translational impact for several human cancers, offering promising drug targets.
Researchers have developed a new treatment combining immunotherapy with lab-cultivated T-cells from patients' blood, which significantly inhibits triple-negative breast cancer growth and metastasis. The treatment has shown promising outcomes in animal models, but further testing in humans is needed to confirm its effectiveness.
Scientists at Northwestern University and UCSF have developed a new technique to enhance the potency of human T cells against cancer. By studying mutations in malignant T cells, they were able to create T cells that can kill tumors derived from skin, lung, and stomach cancers in mice.
Researchers have engineered T cells with a mutation found in malignant lymphoma cells, making them more than 100 times potent at killing cancer cells. The new approach shows promise against solid tumors and could provide long-term immunity against cancer.
Researchers discovered that immune cells called natural killer cells rapidly lose their functionality when entering solid tumours, adopting a dormant state. However, targeting the IL-15 pathway can restore NK cell activity and improve tumor control. This breakthrough could pave the way for new cancer treatments.
Researchers identified senescence-related tumor microenvironment genes associated with poor prognosis, genetic alterations, and reduced responsiveness to immunotherapy in HNSC. The study highlights the importance of precision medicine approaches for personalized treatment.
A recent study discovered a causal link between oncofoetal ecosystems and liver cancer recurrence, highlighting their potential as biomarkers for treating hepatocellular carcinoma (HCC). The research found that oncofoetal reprogramming contributes to EMT, tumour cell proliferation, and response to immunotherapy.
A study reveals thyroid cancer's genetic changes contribute to resistance to BRAF inhibitors and can lead to tumor dedifferentiation. Researchers identify potential targets for new therapies, including dual-targeted treatments and immunotherapy combinations.
A new CRISPR-based technology, TRED-I, has been developed to increase visibility of cancer cells to the immune system by augmenting MHC class I molecules. This technology has shown promising results in animal cancer models, reducing tumor sizes and enhancing treatment efficacy when used with existing immunotherapy.
Researchers have discovered that tumours with mitochondrial DNA mutations are up to two and a half times more likely to respond to immunotherapy, opening a new avenue for improving cancer treatment. This finding could enable doctors to identify patients who would benefit most from immunotherapy before starting treatment.
A phase 3 trial shows that adjuvant pembrolizumab therapy significantly prolongs overall survival in patients with clear-cell renal-cell carcinoma (ccRCC) at high risk for recurrence. The treatment reduces the risk of death by 38% compared to placebo.
Researchers discovered that cisplatin chemotherapy enhances the immune system's ability to fight bladder cancer by modulating the immune response and damaging DNA in cancer cells. This approach may lead to durable disease control in a subset of patients with metastatic bladder cancer.
A recent study published in Cell Reports reveals that cancer cells can prevent the immune system from attacking them by inhibiting key checkpoints. Researchers found that monotherapy agents targeting these checkpoints may not be effective without an inflammatory trigger, explaining why some immunotherapies work while others fail.
Senescent tumour cells generated by chemotherapy can create an environment that helps tumour cells escape treatment. Eliminating these cells with immunotherapy boosts the effectiveness of chemotherapy.
Researchers analyzed LTBR expression levels in various cancers, finding it associated with low patient survival and immune cell infiltration. The study identified LTBR as a potential target for cancer immunotherapy and marker of poor prognosis.
Researchers from Cleveland Clinic and IBM have developed an AI strategy to identify new targets for immunotherapy treatments. The study, published in Briefings in Bioinformatics, reveals how artificial intelligence can be designed to accurately depict how immune systems recognize target antigens.
Researchers have revealed CD4+ T cells can work effectively on their own to control melanoma, challenging conventional understanding. Harnessing their potential therapeutically holds great promise for improving current cancer immunotherapies.
A new study reveals that RNA binding motif protein X-linked (RBMX) plays a crucial role in predicting cancer prognosis and response to immunotherapy. Abnormal expression of RBMX is associated with immune regulation, tumor microenvironment, and therapeutic effects of immune checkpoint inhibitors.
A new computational tool, SNAF, has been developed to identify shared splicing neoantigens that can help a patient's immune system fight cancer. The tool has already uncovered promising targets for melanoma and other cancers.
Researchers analyzed cells within triple-negative breast cancer tumors before and after radiation therapy with immunotherapy, identifying three patient groups with distinct responses. The study found that combining radiation therapy and immunotherapy may improve tumor-fighting immune response prior to surgery for some patients.
A new study from Sylvester Comprehensive Cancer Center suggests that prophylactic treatment can significantly reduce the rate of cytokine release syndrome (CRS) in multiple myeloma patients. This approach could eliminate hospital stays and broaden access to immunotherapy treatments for more cancer patients.
Scientists have mapped neuroblastoma tumors at the cell level and discovered a brake on the immune system that can be blocked with existing immunotherapy. A new combination treatment targeting TIGIT and PD-L1 is being developed, showing promising results in lab experiments.
Researchers found that a rare type of T cell, Vd1-gd T cells, can predict patient response to immunotherapy treatments. The presence of these cells is highly predictive of positive responses in cancers with few mutations, and they may be more resistant to suppression from cancer cells.
Researchers at Brigham and Women's Hospital found nearly 6,000 additional US patients could benefit from immunotherapy treatment due to mismatch repair deficiency. Next-generation sequencing revealed previously missed cases, improving patient outcomes.
Researchers from Brazil discuss the management of refractory or relapsed classic Hodgkin lymphoma in adults, highlighting novel agents such as brentuximab vedotin and immunotherapy. The Brazilian healthcare system's constraints are also considered when making treatment decisions.
New research reveals that Black women are more likely to develop endometrial cancers called serous carcinoma and carcinosarcoma, which are more aggressive than those found in white women. The study also showed that Black patients have a higher risk of having copy number-high or TP53 abnormal tumors, which have worse outcomes.
Researchers at Kobe University developed a new model of mice with humanized immune systems to test anti-cancer drugs targeting the immune system. The study showed that a therapy blindfolding immune cells to self-recognition can activate them to attack tumor cells, promoting an effective cancer response.
A U of M-led study introduces an innovative genetic engineering method that avoids cost and safety concerns associated with viral vectors. The method combines CRISPR-Cas9 precision genome editing and a novel DNA integration mechanism, integrating large DNA sequences into human T-cells with high efficiency.
A new study found that perivascular fibroblasts support the creation of an immunosuppressive tumor microenvironment, allowing glioblastoma to evade the immune system. The fibroblasts may also promote stem-like cancer cells that rarely divide, leading to poor survival outcomes.
A new study suggests that metastatic prostate tumors contain a rich variety of immune cells that can be roused by immunotherapy into attacking the cancer. Combining hormone therapy with immunotherapy further stimulates anti-tumor immune cells, potentially improving patient outcomes.
Researchers at Johns Hopkins Medicine used liquid biopsies to monitor changes in circulating tumor DNA and detect immune cell expansions, predicting patient responses to immunotherapies and detecting early signs of toxic side effects. The test showed significant associations with progression-free and overall survival.
A new study from Indian Institute of Science finds that certain types of cancer cells respond well to IFN-γ activation, while others don't. The researchers suggest approaches to make non-responsive cancer cells better respond to immunotherapy by targeting their metabolism.